Latest investments

Date
Company Name
Company Activities
18-01-2018
Lidds

LIDDS AB  develops efficient drugs for cancer and other diseases based on our unique proprietary NanoZolid® technology. NanoZolid helps solve some of the main problems with the way drugs work in the body and affect the patients’ quality of life. NanoZolid enables controlled, long-term and personalized release of the drug for up to six months. NanoZolid can be combined with traditional small molecules as well as with large biological molecules such as antibodies.

Click here to read more

23-12-2017
Mithra

Mithra is dedicated to providing innovation and choice in women’s health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta® – are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO.

Click here to read more

11-12-2017
Carmat

CARMAT is developing a orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. The objective is to meet a world-wide public healthcare need, that is to say the treatment of advanced heart failure

Click here to read more

15-11-2017
Transgene

Transgene focuses on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.

Click here to read more

06-06-2017
Sedana Medical

Sedana Medical’s vision is to develop inhalation sedation with its products AnaConDa and IsoConDa into a global standard model for the sedation of mechanically ventilated patients in intensive care. The company hopes to realise this ambitious vision by offering, with the AnaConDa technology and the medicinal product IsoConDa (isoflurane), a solution that addresses the problems that present-day intravenous sedatives cause or do not solve sufficiently well.

Click here to read more